PEAK: Panitumumab Plus mFOLFOX6 vs. Bevacizumab Plus mFOLFOX6 for First Line Treatment of Metastatic Colorectal Cancer (mCRC) Patients With Wild-Type Kirsten Rat Sarcoma-2 Virus (KRAS) Tumors

NCT00819780 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

285

Enrollment

INDUSTRY

Sponsor class

Conditions

Colon Cancer
Colorectal Cancer
Rectal Cancer
Metastatic Colorectal Cancer

Interventions

DRUG: Panitumumab
DRUG: Bevacizumab
DRUG: mFOLFOX6

Sponsor

Amgen